Bioventus Inc. (NYSE:BVS) Holdings Reduced by Nantahala Capital Management LLC

Nantahala Capital Management LLC cut its stake in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 8.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,338,314 shares of the company's stock after selling 467,698 shares during the quarter. Bioventus comprises approximately 1.8% of Nantahala Capital Management LLC's portfolio, making the stock its 6th biggest position. Nantahala Capital Management LLC owned approximately 6.74% of Bioventus worth $30,695,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Acadian Asset Management LLC bought a new position in shares of Bioventus during the first quarter valued at $28,000. Lazard Asset Management LLC bought a new stake in Bioventus in the 1st quarter worth about $40,000. HB Wealth Management LLC bought a new stake in Bioventus in the 2nd quarter worth about $60,000. SG Americas Securities LLC bought a new stake in Bioventus in the 1st quarter worth about $66,000. Finally, Burns Matteson Capital Management LLC bought a new stake in Bioventus in the 2nd quarter worth about $67,000. 62.94% of the stock is currently owned by institutional investors.

Bioventus Stock Performance

NYSE:BVS traded down $0.16 on Tuesday, hitting $11.79. The stock had a trading volume of 634,365 shares, compared to its average volume of 392,789. The stock has a market cap of $933.37 million, a price-to-earnings ratio of -33.74 and a beta of 0.89. The company has a quick ratio of 0.96, a current ratio of 1.33 and a debt-to-equity ratio of 1.82. The business's 50-day simple moving average is $9.32 and its two-hundred day simple moving average is $6.94. Bioventus Inc. has a 52-week low of $2.85 and a 52-week high of $12.41.

Bioventus (NYSE:BVS - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.12. The business had revenue of $151.22 million for the quarter, compared to analysts' expectations of $137.70 million. Bioventus had a positive return on equity of 14.39% and a negative net margin of 7.82%. During the same period last year, the firm posted $0.14 earnings per share. As a group, research analysts predict that Bioventus Inc. will post 0.4 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director John A. Bartholdson acquired 25,500 shares of the stock in a transaction dated Monday, August 19th. The shares were purchased at an average cost of $8.55 per share, with a total value of $218,025.00. Following the transaction, the director now directly owns 6,939,357 shares in the company, valued at $59,331,502.35. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director John A. Bartholdson acquired 25,500 shares of the stock in a transaction dated Monday, August 19th. The shares were purchased at an average cost of $8.55 per share, with a total value of $218,025.00. Following the transaction, the director now directly owns 6,939,357 shares in the company, valued at $59,331,502.35. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director John A. Bartholdson acquired 80,000 shares of the stock in a transaction dated Friday, August 16th. The shares were bought at an average cost of $8.55 per share, for a total transaction of $684,000.00. Following the completion of the transaction, the director now owns 6,913,857 shares in the company, valued at $59,113,477.35. The disclosure for this purchase can be found here. Insiders own 32.90% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on BVS shares. Canaccord Genuity Group lifted their price objective on Bioventus from $8.00 to $12.00 and gave the stock a "buy" rating in a report on Tuesday, August 13th. Craig Hallum lifted their price objective on Bioventus from $12.00 to $17.00 and gave the stock a "buy" rating in a report on Friday.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.